Allspring Global Investments Holdings LLC Has $2.73 Million Stock Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Allspring Global Investments Holdings LLC lessened its stake in shares of SI-BONE, Inc. (NASDAQ:SIBNFree Report) by 64.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 166,720 shares of the company’s stock after selling 302,766 shares during the period. Allspring Global Investments Holdings LLC owned 0.41% of SI-BONE worth $2,729,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SIBN. RiverPark Advisors LLC increased its position in SI-BONE by 22.6% in the 4th quarter. RiverPark Advisors LLC now owns 3,151 shares of the company’s stock valued at $66,000 after buying an additional 580 shares in the last quarter. Amalgamated Bank increased its holdings in shares of SI-BONE by 12.9% during the fourth quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock valued at $123,000 after acquiring an additional 673 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of SI-BONE by 14.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock worth $179,000 after purchasing an additional 1,106 shares during the period. Arizona State Retirement System lifted its holdings in shares of SI-BONE by 7.7% in the 4th quarter. Arizona State Retirement System now owns 10,675 shares of the company’s stock worth $224,000 after purchasing an additional 762 shares in the last quarter. Finally, Semanteon Capital Management LP acquired a new stake in SI-BONE in the 4th quarter valued at $251,000. Institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $27.00 price objective on shares of SI-BONE in a report on Tuesday, May 7th. Morgan Stanley lowered their target price on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, May 7th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of SI-BONE in a research note on Tuesday, May 7th. Finally, Piper Sandler began coverage on SI-BONE in a research note on Thursday, March 28th. They issued an “overweight” rating and a $25.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $26.33.

View Our Latest Stock Report on SI-BONE

SI-BONE Stock Up 0.8 %

Shares of SIBN stock opened at $13.00 on Wednesday. SI-BONE, Inc. has a 52-week low of $11.76 and a 52-week high of $27.86. The company has a 50-day simple moving average of $13.76 and a two-hundred day simple moving average of $16.80. The company has a quick ratio of 8.75, a current ratio of 9.76 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBNGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $37.87 million during the quarter, compared to the consensus estimate of $36.45 million. SI-BONE had a negative return on equity of 25.14% and a negative net margin of 29.93%. As a group, sell-side analysts forecast that SI-BONE, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Transactions at SI-BONE

In related news, CFO Anshul Maheshwari sold 2,441 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.14, for a total transaction of $36,956.74. Following the completion of the transaction, the chief financial officer now owns 204,241 shares in the company, valued at $3,092,208.74. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, insider Anthony J. Recupero sold 3,941 shares of SI-BONE stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.10, for a total value of $59,509.10. Following the sale, the insider now owns 247,592 shares of the company’s stock, valued at approximately $3,738,639.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Anshul Maheshwari sold 2,441 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.14, for a total value of $36,956.74. Following the completion of the transaction, the chief financial officer now owns 204,241 shares in the company, valued at approximately $3,092,208.74. The disclosure for this sale can be found here. Insiders have sold 8,647 shares of company stock worth $129,803 in the last ninety days. Company insiders own 5.40% of the company’s stock.

SI-BONE Profile

(Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Featured Stories

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.